These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 577309)

  • 1. Bromocriptin and methylergometrine: pharmacological approach of the mechanism of their central effects.
    Puech AJ; Simon P; Chermat R; Boissier JR
    Pharmacol Res Commun; 1977 Mar; 9(3):299-306. PubMed ID: 577309
    [No Abstract]   [Full Text] [Related]  

  • 2. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Jan; 56(1):59-68. PubMed ID: 943193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine.
    Loew DM; Jaton AL; Vigouret JM
    Postgrad Med J; 1976; 52suppl 1():40-46. PubMed ID: 822407
    [No Abstract]   [Full Text] [Related]  

  • 4. Pre- and postsynaptic action of bromocriptine: its pharmacological effects on shcizophrenia and neurological diseases.
    Trabucchi M; Andreoli VM; Frattola L; Spano PF
    Adv Biochem Psychopharmacol; 1977; 16():661-5. PubMed ID: 196497
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychopharmacological profile of mesterolone.
    Baran L; Przegaliński E
    Pol J Pharmacol Pharm; 1981 Oct; 33(3):299-303. PubMed ID: 7198778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride.
    Wachtel H; Dorow R
    Life Sci; 1983 Jan; 32(4):421-32. PubMed ID: 6827903
    [No Abstract]   [Full Text] [Related]  

  • 7. Catalepsy and stereotypies in rats treated with methadone; relation to striatal dopamine.
    Ahtee L
    Eur J Pharmacol; 1974 Jul; 27(2):221-30. PubMed ID: 4859239
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and pharmacological properties of new derivatives of 1-diphenylacetamide-2-butanol.
    Kolasa K; Kleinrok Z; Pietrasiewicz T; Czechowska G; Zejc A; Gajewczyk L
    Pol J Pharmacol Pharm; 1989; 41(5):475-81. PubMed ID: 2577062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between ethanol and amphetamine in mice and rats.
    Spreux-Varoquaux O; Simon P
    Prog Neuropsychopharmacol; 1980; 4(1):13-8. PubMed ID: 7190719
    [No Abstract]   [Full Text] [Related]  

  • 10. Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712.
    Vigouret JM; Bürki HR; Jaton AL; Züger PE; Loew DM
    Pharmacology; 1978; 16 Suppl 1():156-73. PubMed ID: 565520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.
    Johnson AM; Vigouret JM; Loew DM
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R40. PubMed ID: 4276573
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological properties of substituted gamma-butyrolactones. I. The effects on the central nervous system.
    Sieroslawska J; Hano J; Sypniewska M; Czarnecki R; Chojnacka-Wójcik E; Harasiewicz A
    Pol J Pharmacol Pharm; 1973; 25(1):1-16. PubMed ID: 4798097
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of three dopamine agonists on cage climbing behavior.
    Gianutsos G; Palmeri JL
    Psychopharmacology (Berl); 1983; 79(4):329-31. PubMed ID: 6134299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On some central effects of elymoclavine.
    Roussinov K; Georgiev V; Petkov V; Lazarova M; Petkova B; Shopova S; Markovska V; Getova D; Draganova S
    Acta Physiol Pharmacol Bulg; 1984; 10(4):28-35. PubMed ID: 6442955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
    Maj J; Sowińska H; Baran L; Sarnek J
    Eur J Pharmacol; 1974 Apr; 26(1):9-14. PubMed ID: 4857604
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings].
    Jaton AL; Loew DM; Vigouret JM
    Br J Pharmacol; 1978 Mar; 62(3):395P. PubMed ID: 565235
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacological study of a possible dopamine metabolite, tetrahydropapaveroline].
    Simon P; Goujet MA; Chermat R; Boissier JR
    Therapie; 1971; 26(6):1175-92. PubMed ID: 5146531
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis of new arylanalogs of ketamine.
    Burak K; Lipnicka U; Orszańska H; Rykowski Z; Witkiewicz K; Wrzesień J; Bogdal M; Krzywasiński L; Borkowska B
    Farmaco Sci; 1985 Apr; 40(4):285-98. PubMed ID: 4040474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of L-dopa and lergotrile mesylate on the interaction of fluphenazine decanoate and amphetamine-induced stereotypy and mortality.
    Lemberger L; Kellams JJ; Small JG; Rowe H
    Commun Psychopharmacol; 1977; 1(5):501-7. PubMed ID: 564259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.